N2OFF's 15min Chart Triggers Bollinger Bands Narrowing, KDJ Death Cross, Bearish Marubozu

As per the 15-minute chart of N2OFF, the Bollinger Bands have narrowed, which signifies a reduction in the magnitude of stock price fluctuations. Additionally, the KDJ indicator has formed a death cross, and the stock has exhibited a bearish Marubozu pattern at 10/03/2025 13:45. These indicators collectively suggest that the momentum of the stock price is shifting towards the downside and may further decrease in the near future. Sellers appear to be in control of the market, and it is likely that the bearish momentum will persist.

N2OFF, Inc. (NASDAQ: NITO) shareholders have approved the acquisition of SciSparc Ltd.'s (Nasdaq: SPRC) majority-owned subsidiary, MitoCareX Bio Ltd. SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[1]. This strategic move positions N2OFF to enter the lucrative oncology market, while providing SciSparc with both immediate cash consideration and significant long-term upside potential.

The acquisition involves a $700,000 cash payment for 6,622 shares of MitoCareX and an equity exchange giving sellers 40% of N2OFF's fully diluted capital stock. Additionally, sellers will receive 30% of N2OFF's financing proceeds (capped at $1.6 million) over five years, plus milestone-based issuances of up to 25% of N2OFF's common stock SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[1].

MitoCareX's scientific approach targets the mitochondrial SLC25 protein family, offering a differentiated strategy in oncology. Their combined computational modeling and in-vitro screening platform could potentially identify novel therapeutics for resistant cancers, including pancreatic and non-small cell lung cancer - areas with significant unmet medical needs SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[1].

The global cancer therapeutics market is projected to grow from $194.1 billion in 2024 to $344.1 billion by 2031 SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[1]. However, early-stage drug discovery carries significant technical and regulatory risks, with no guaranteed timeline to market. N2OFF has committed to a $1 million initial investment to support MitoCareX's operations post-closing, providing operational runway, but additional funding will likely be needed for clinical development SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer^[1].

Technical Analysis:
As of September 12, 2025, N2OFF's 15-minute chart indicates narrowing Bollinger Bands, suggesting a reduction in stock price fluctuations. The KDJ indicator has formed a death cross, and the stock exhibited a bearish Marubozu pattern on October 3, 2025, at 13:45. These indicators collectively suggest that the momentum of the stock price is shifting towards the downside and may further decrease in the near future .